Fielder Capital Group LLC Purchases New Position in Danaher Co. (NYSE:DHR)

Fielder Capital Group LLC bought a new stake in Danaher Co. (NYSE:DHR) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 878 shares of the conglomerate’s stock, valued at approximately $203,000.

Other hedge funds also recently modified their holdings of the company. Wellington Management Group LLP lifted its position in shares of Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Allen Investment Management LLC lifted its holdings in Danaher by 1,440.7% during the third quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock worth $273,009,000 after acquiring an additional 1,028,976 shares during the period. J.P. Morgan Private Wealth Advisors LLC purchased a new position in Danaher in the third quarter worth $178,850,000. Alecta Tjanstepension Omsesidigt bought a new position in Danaher in the 4th quarter valued at $161,994,000. Finally, Harris Associates L P increased its position in shares of Danaher by 27.7% during the 3rd quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock valued at $735,343,000 after purchasing an additional 642,759 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

NYSE:DHR traded down $0.98 during trading hours on Monday, hitting $247.40. The stock had a trading volume of 1,593,955 shares, compared to its average volume of 2,755,556. The company has a 50 day simple moving average of $248.40 and a two-hundred day simple moving average of $232.89. The firm has a market capitalization of $183.25 billion, a price-to-earnings ratio of 41.93, a P/E/G ratio of 3.82 and a beta of 0.83. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a one year low of $182.09 and a one year high of $259.00.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The company’s quarterly revenue was down 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.36 EPS. Research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Transactions at Danaher

In other Danaher news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares of the company’s stock, valued at $28,908,273.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Danaher news, Director Walter G. Lohr sold 3,289 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the completion of the sale, the director now directly owns 14,129 shares of the company’s stock, valued at $3,548,498.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 107,273 shares of company stock valued at $26,813,819. Insiders own 10.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. KeyCorp increased their price target on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Citigroup lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Raymond James increased their price objective on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, January 31st. Bank of America boosted their target price on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Finally, Robert W. Baird increased their price target on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average target price of $267.31.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.